<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02870153</url>
  </required_header>
  <id_info>
    <org_study_id>CZYY-CRC-007</org_study_id>
    <nct_id>NCT02870153</nct_id>
  </id_info>
  <brief_title>SOX Versus XELOX for Patients With Peritoneal Metastasis of Colorectal Cancer</brief_title>
  <official_title>A Randomized Phase II Study of Oxaliplatin and S-1 (SOX) Versus Oxaliplatin and Capecitabine (XELOX) in Patients With Peritoneal Metastasis of Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First People's Hospital of Changzhou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First People's Hospital of Changzhou</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the activity and safety of Oxaliplatin and S-1 (SOX) and
      Oxaliplatin and Capecitabine (XELOX) in patients with peritoneal metastasis of colorectal
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peritoneal dissemination from colorectal cancer is common, and it has been traditionally
      regarded as end-stage disease only amenable to palliation by systemic chemotherapy (sCT), or
      supportive care .Oxaliplatin and oral fluoropyrimidines (capecitabine or S-1) are active
      agents for colorectal cancer. Recent a phase II trial of combination chemotherapy of
      oxaliplatin with S-1 (OS) and several phase II trial of combination chemotherapy of
      oxaliplatin with capecitabine (XELOX) demonstrated good activity and mild toxicity in
      advanced colorectal cancer. Oxaliplatin and S-1 or capecitabine have distinct mechanisms of
      action and no overlap of key toxicities. Furthermore, oxaliplatin and fluorouracil were shown
      to be highly synergistic, not only in preclinical models but also in subsequent clinical
      trials.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>6 weeks</time_frame>
    <description>According to the RECIST criterion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side-effect</measure>
    <time_frame>8 weeks</time_frame>
    <description>Safety was evaluated according to the NCI-CTC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>6 years</time_frame>
    <description>According to the RECIST criterion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>6 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Colorectal Neoplasm</condition>
  <arm_group>
    <arm_group_label>SOX(oxalipaltin+S-1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO [BSA &lt;1.25 40mg bid (total 80mg/day); BSA ≥1.25 - &lt;1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)], divided by two on D1-14 every 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XELOX (oxalipaltin+capecitabine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOX</intervention_name>
    <description>Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO [BSA &lt;1.25 40mg bid (total 80mg/day); BSA ≥1.25 - &lt;1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)], divided by two on D1-14 every 21 days</description>
    <arm_group_label>SOX(oxalipaltin+S-1)</arm_group_label>
    <other_name>Eloxatin</other_name>
    <other_name>TS-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XELOX</intervention_name>
    <description>Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days</description>
    <arm_group_label>XELOX (oxalipaltin+capecitabine)</arm_group_label>
    <other_name>Eloxatin</other_name>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Histologically confirmed colorectal adenocarcinoma, initially diagnosed or recurred

        Peritoneal metastasis of colorectal cancer

        At least one uni-dimensional measurable lesion by RECIST criteria

        Age 18 to 80 years old

        Estimated life expectancy ≥3 months

        ECOG performance status ≤2

        Adequate bone marrow function (WBCs ≥ 4,000/µL or absolute neutrophil count ≥ 1,500/µL,
        platelets ≥ 100,000/µL)

        Adequate kidney function (creatinine &lt; 1.5 mg/dL)

        Adequate liver function (bilirubin &lt; 2.0 mg/dL, transaminase levels &lt;2.5 times the upper
        normal limit)

        Written informed consent

        Exclusion Criteria:

        Other tumor type than adenocarcinoma

        Previous history of chemotherapy (exception : neoadjuvant or adjuvant chemotherapy without
        oxaliplatin)

        Presence of CNS metastasis, psychosis, or seizure

        Obvious bowel obstruction

        Evidence of serious gastrointestinal bleeding

        Past or concurrent history of neoplasm other than colorectal adenocarcinoma, except for
        curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix uteri

        Pregnant or lactating women, women of childbearing potential not employing adequate
        contraception

        Other serious illness or medical conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Changping Wu, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>The First People's Hospital of Changzhou</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiemin Zhao, M.D.</last_name>
    <phone>86-519-68871122</phone>
    <email>210328010@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liangrong Shi, M.D.</last_name>
    <phone>86-519-68871122</phone>
    <email>doctorslr@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First People's Hospital of Changzhou</name>
      <address>
        <city>Changzhou</city>
        <state>Jiangsu</state>
        <zip>213003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liangrong Shi, M.D.</last_name>
      <phone>86-519-68871122</phone>
      <email>shiliangr@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Baratti D, Kusamura S, Pietrantonio F, Guaglio M, Niger M, Deraco M. Progress in treatments for colorectal cancer peritoneal metastases during the years 2010-2015. A systematic review. Crit Rev Oncol Hematol. 2016 Apr;100:209-22. doi: 10.1016/j.critrevonc.2016.01.017. Epub 2016 Jan 22. Review.</citation>
    <PMID>26867984</PMID>
  </reference>
  <reference>
    <citation>Esquivel J. Colorectal cancer with peritoneal metastases: Progress, not perfection. J Surg Oncol. 2015 Jul;112(1):115. doi: 10.1002/jso.23954. Epub 2015 Jul 7.</citation>
    <PMID>26153356</PMID>
  </reference>
  <reference>
    <citation>Ogawa M, Anan T, Suzuki T, Okuma M, Ichihara K, Hasegawa T, Yoshida K, Yanaga K. Initial Report of Phase II Study on Bi-weekly SOX plus Cetuximab Treatment for Wild-type K-RAS Advanced and Recurrent Colorectal Cancer. Anticancer Res. 2016 May;36(5):2505-11.</citation>
    <PMID>27127165</PMID>
  </reference>
  <reference>
    <citation>Wang ZQ, Zhang DS, Xu N, Luo DY, Deng YH, Wang FH, Luo HY, Qiu MZ, Li YH, Xu RH. Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer. Chin J Cancer. 2016 Jan 6;35:8. doi: 10.1186/s40880-015-0061-3.</citation>
    <PMID>26739998</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2016</study_first_submitted>
  <study_first_submitted_qc>August 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2016</study_first_posted>
  <last_update_submitted>August 17, 2016</last_update_submitted>
  <last_update_submitted_qc>August 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

